



October 3, 2022
JCR Pharmaceuticals Co., Ltd.

Translation

Notice of Selection as METI “Project for Establishing Biopharmaceutical Manufacturing Sites to Strengthen Vaccine Production”

October 3 -- JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that it applied for a “Grant for Projects for Establishing Biopharmaceutical Manufacturing Sites to Strengthen Vaccine Production,” by the Ministry of Economy, Trade, and Industry (METI) and that on September 30 the project application was granted funding. The Company will use the grant to construct a new plant for drug product filling and finishing in Kobe Science Park.

1. Details of the Selected Project

- i) Project Name:
Project for Establishing Biopharmaceutical Manufacturing Sites to Strengthen Vaccine Production
- ii) Project Details:
To establish a flexible fill and finish plant for vaccines against infectious diseases that could pose a threat in the future. The site is expected to fulfill dual purpose: vaccine fill and finish during potential upcoming pandemics and manufacturing biopharmaceutical products in the regular course of business. In addition, the knowledge and know-how established will assist other companies to establish similar capabilities in case of a major outbreak of a pandemic. The project is a natural extension of the new manufacturing plant for vaccines in Kobe Science Park that was also supported by a grant from the Ministry of Health, Labour and Welfare (MHLW).
- iii) Amount of grant funding to be allocated:
To be notified promptly once determined
- iv) Planned execution period for the project:
January 1, 2023, to April 30, 2026

2. Reason for applying for the Project

JCR is full-fledged bio-pharma with capabilities from research and development to manufacturing. During the COVID-19 pandemic JCR made its biomanufacturing capacities and knowledge available to manufacture the vaccine solution for Japan and other Asian Countries. With the funding of the fill and finish plant, JCR will be strategically well prepared and equipped to manufacture vaccines for Japan and potentially other countries in case of an outbreak of another pandemic. In times when vaccine manufacturing will not be required, JCR will use the production capacities for the biomanufacturing of products that are based on the proprietary blood-brain-barrier penetrating technology, J-Brain Cargo[®]. With the grant from METI, JCR will be able to upgrade its production capabilities for in-house formulations and respond to demand in-house biopharmaceutical formulations as well as for future vaccine

demand. We believe that this manufacturing system will contribute to the rapid and stable supply of vaccines in the event of a pandemic for infectious diseases in Japan.

3. Future Outlook

Having been selected for this Project, JCR will expeditiously prepare the construction of the new plant. Details will be announced promptly after the Board of Directors' resolution.

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 48-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II (Hunter syndrome), MPS III A and B (Sanfilippo type A and B), and other lysosomal storage diseases. JCR strives to expand the possibilities for treating patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Contact:

Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jcrpharm.co.jp

###